{"id":"https://openalex.org/W4405038457","doi":"https://doi.org/10.1182/blood-2024-201543","title":"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial","display_name":"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial","publication_year":2024,"publication_date":"2024-11-05","ids":{"openalex":"https://openalex.org/W4405038457","doi":"https://doi.org/10.1182/blood-2024-201543"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2024-201543","doi":"https://doi.org/10.1182/blood-2024-201543","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2024-201543","pdf_url":"https://ashpublications.org/blood/article-pdf/144/Supplement 1/3359/2338754/blood-6111-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ashpublications.org/blood/article-pdf/144/Supplement 1/3359/2338754/blood-6111-main.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103172552","display_name":"V\u00e2nia Hungria","orcid":"https://orcid.org/0000-0002-4327-1957","observed_orcids":["https://orcid.org/0000-0002-4327-1957"]},"institutions":[{"id":"https://openalex.org/I4210112463","display_name":"S\u00e3o Germano Oncologia","ror":"https://ror.org/01dh8xz10","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210112463"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Vania Hungria","raw_affiliation_strings":["1Clinica S\u00e3o Germano, S\u00e3o Paulo, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Clinica S\u00e3o Germano, S\u00e3o Paulo, Brazil","institution_ids":["https://openalex.org/I4210112463"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033354752","display_name":"Marek Hus","orcid":"https://orcid.org/0000-0002-9036-6625","observed_orcids":["https://orcid.org/0000-0002-9036-6625"]},"institutions":[{"id":"https://openalex.org/I121032520","display_name":"Medical University of Lublin","ror":"https://ror.org/016f61126","country_code":"PL","type":"education","lineage":["https://openalex.org/I121032520"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Marek Hus","raw_affiliation_strings":["2Medical University of Lublin, Lublin, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Medical University of Lublin, Lublin, Poland","institution_ids":["https://openalex.org/I121032520"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017586611","display_name":"Pawel J. Robak","orcid":"https://orcid.org/0000-0002-6078-5415","observed_orcids":["https://orcid.org/0000-0002-6078-5415"]},"institutions":[{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Pawel Robak","raw_affiliation_strings":["3Medical University of Lodz, Lodz, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Medical University of Lodz, Lodz, Poland","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040499157","display_name":"\u0416\u0435\u0440\u0435\u0431\u0446\u043e\u0432\u0430 \u0412\u0435\u0440\u0430 \u0410\u043d\u0430\u0442\u043e\u043b\u044c\u0435\u0432\u043d\u0430","orcid":"https://orcid.org/0000-0002-3052-269X","observed_orcids":["https://orcid.org/0000-0002-3052-269X"]},"institutions":[{"id":"https://openalex.org/I4210121251","display_name":"Botkin Hospital","ror":"https://ror.org/01xbp4f63","country_code":"RU","type":"healthcare","lineage":["https://openalex.org/I4210121251"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Vera Zherebtsova","raw_affiliation_strings":["4Gorodskaya Klinicheskaya Bol'nitsa Im. S.p. Botkina, Moscow, Russian Federation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Gorodskaya Klinicheskaya Bol'nitsa Im. S.p. Botkina, Moscow, Russian Federation","institution_ids":["https://openalex.org/I4210121251"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ana Carolina de Almeida Ribas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Carolina de Almeida Ribas","raw_affiliation_strings":["5Centro de Pesquisa e Ensino em Sa\u00fade de Santa Catarin, Florian\u00f3polis, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Centro de Pesquisa e Ensino em Sa\u00fade de Santa Catarin, Florian\u00f3polis, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084502515","display_name":"Marcelo Pitombeira de Lacerda","orcid":"https://orcid.org/0000-0001-5554-7167","observed_orcids":["https://orcid.org/0000-0001-5554-7167"]},"institutions":[{"id":"https://openalex.org/I4210100389","display_name":"Universidade da Regi\u00e3o de Joinville","ror":"https://ror.org/00je1p681","country_code":"BR","type":"education","lineage":["https://openalex.org/I4210100389"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Marcelo Pitombeira de Lacerda","raw_affiliation_strings":["6Universidade da Regi\u00e3o de Joinville (Univille), Joinville, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Universidade da Regi\u00e3o de Joinville (Univille), Joinville, Brazil","institution_ids":["https://openalex.org/I4210100389"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100353399","display_name":"Kihyun K\u0131m","orcid":"https://orcid.org/0000-0002-5878-8895","observed_orcids":["https://orcid.org/0000-0002-5878-8895"]},"institutions":[{"id":"https://openalex.org/I2802194831","display_name":"Samsung Medical Center","ror":"https://ror.org/05a15z872","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2250650973","https://openalex.org/I2802194831"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Kihyun Kim","raw_affiliation_strings":["7Sungkyunkwan University, Samsung Medical Center, Seoul, Korea, Republic of (South)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Sungkyunkwan University, Samsung Medical Center, Seoul, Korea, Republic of (South)","institution_ids":["https://openalex.org/I2802194831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062322697","display_name":"Sebastian Grosicki","orcid":"https://orcid.org/0000-0003-2644-1050","observed_orcids":["https://orcid.org/0000-0003-2644-1050"]},"institutions":[{"id":"https://openalex.org/I166182418","display_name":"Medical University of Silesia","ror":"https://ror.org/005k7hp45","country_code":"PL","type":"education","lineage":["https://openalex.org/I166182418"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Sebastian Grosicki","raw_affiliation_strings":["8Medical University of Silesia, Katowice, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Medical University of Silesia, Katowice, Poland","institution_ids":["https://openalex.org/I166182418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043785211","display_name":"Irwindeep Sandhu","orcid":"https://orcid.org/0000-0001-9407-6265","observed_orcids":["https://orcid.org/0000-0001-9407-6265"]},"institutions":[{"id":"https://openalex.org/I154425047","display_name":"University of Alberta","ror":"https://ror.org/0160cpw27","country_code":"CA","type":"education","lineage":["https://openalex.org/I154425047"]},{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Irwindeep Sandhu","raw_affiliation_strings":["9University of Alberta, Cross Cancer Institute, Edmonton, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9University of Alberta, Cross Cancer Institute, Edmonton, Canada","institution_ids":["https://openalex.org/I154425047","https://openalex.org/I4405258411"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101445996","display_name":"Christopher W\u00e5rd","orcid":"https://orcid.org/0000-0003-4929-1200","observed_orcids":["https://orcid.org/0000-0003-4929-1200"]},"institutions":[{"id":"https://openalex.org/I2800079252","display_name":"Royal North Shore Hospital","ror":"https://ror.org/02gs2e959","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800079252"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Christopher Ward","raw_affiliation_strings":["10Royal North Shore Hospital, Sydney, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Royal North Shore Hospital, Sydney, NSW, Australia","institution_ids":["https://openalex.org/I2800079252"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001577825","display_name":"Astrid McKeown","orcid":"https://orcid.org/0009-0007-7240-4708","observed_orcids":["https://orcid.org/0009-0007-7240-4708"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Astrid McKeown","raw_affiliation_strings":["11GSK, Stevenage, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11GSK, Stevenage, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113236473","display_name":"Hena Baig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126541","display_name":"GlaxoSmithKline (Canada)","ror":"https://ror.org/02zz8mw60","country_code":"CA","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210126541"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Hena Baig","raw_affiliation_strings":["12GSK, Mississauga, CAN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12GSK, Mississauga, CAN","institution_ids":["https://openalex.org/I4210126541"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048662409","display_name":"Jie Ma","orcid":"https://orcid.org/0009-0008-6213-5687","observed_orcids":["https://orcid.org/0009-0008-6213-5687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Ma","raw_affiliation_strings":["13GSK, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13GSK, Waltham, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115005660","display_name":"Benjamin Lariviere","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Lariviere","raw_affiliation_strings":["13GSK, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13GSK, Waltham, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020620994","display_name":"Benga Kazeem","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benga Kazeem","raw_affiliation_strings":["11GSK, Stevenage, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11GSK, Stevenage, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066026746","display_name":"Lydia Eccersley","orcid":"https://orcid.org/0000-0002-2555-0725","observed_orcids":["https://orcid.org/0000-0002-2555-0725"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lydia Eccersley","raw_affiliation_strings":["14GSK, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14GSK, London, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038245025","display_name":"Sumita Roy\u2013Ghanta","orcid":"https://orcid.org/0009-0007-9452-1139","observed_orcids":["https://orcid.org/0009-0007-9452-1139"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sumita Roy-Ghanta","raw_affiliation_strings":["15GSK, Upper Providence, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15GSK, Upper Providence, PA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023624767","display_name":"Joanna Opalinska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanna Opalinska","raw_affiliation_strings":["16GSK, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16GSK, Philadelphia, PA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029159537","display_name":"Mar\u00eda\u2010Victoria Mateos","orcid":"https://orcid.org/0000-0003-2390-1218","observed_orcids":["https://orcid.org/0000-0003-2390-1218"]},"institutions":[{"id":"https://openalex.org/I4210134045","display_name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","ror":"https://ror.org/03em6xj44","country_code":"ES","type":"facility","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034","https://openalex.org/I4210134045"]},{"id":"https://openalex.org/I4210138819","display_name":"Centro de Investigaci\u00f3n del C\u00e1ncer","ror":"https://ror.org/04rxrdv16","country_code":"ES","type":"facility","lineage":["https://openalex.org/I134820265","https://openalex.org/I184999862","https://openalex.org/I4210138819"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Maria Victoria Mateos","raw_affiliation_strings":["17Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"17Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain","institution_ids":["https://openalex.org/I4210134045","https://openalex.org/I4210138819"]}]}],"institutions":[],"countries_distinct_count":9,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"144","issue":"Supplement 1","first_page":"3359","last_page":"3359"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/minimal-residual-disease-negativity","display_name":"minimal residual disease negativity","score":0.902999997138977},{"id":"https://openalex.org/keywords/belantamab-mafodotin","display_name":"belantamab mafodotin","score":0.9940000176429749},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9279999732971191},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9419999718666077},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9929999709129333},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9860000014305115},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5960000157356262},{"id":"https://openalex.org/keywords/very-good-partial-response","display_name":"very good partial response","score":0.9100000262260437},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.5789999961853027},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.908866286277771},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9049201011657715},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.7998826503753662},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.744331955909729},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.711794912815094},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6538930535316467},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6469637155532837},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.5992089509963989},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5098502039909363},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.4813171625137329},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.13078171014785767},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06686598062515259},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2024-201543","doi":"https://doi.org/10.1182/blood-2024-201543","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2024-201543","pdf_url":"https://ashpublications.org/blood/article-pdf/144/Supplement 1/3359/2338754/blood-6111-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1182/blood-2024-201543","doi":"https://doi.org/10.1182/blood-2024-201543","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2024-201543","pdf_url":"https://ashpublications.org/blood/article-pdf/144/Supplement 1/3359/2338754/blood-6111-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4405038457.pdf","grobid_xml":"https://content.openalex.org/works/W4405038457.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417012482","https://openalex.org/W7202353097","https://openalex.org/W4410795580","https://openalex.org/W4412461073","https://openalex.org/W7204690948","https://openalex.org/W7162541824","https://openalex.org/W7108604932","https://openalex.org/W4392284807","https://openalex.org/W4399480854","https://openalex.org/W4405043193"],"abstract_inverted_index":{"Background:":[0],"In":[1,86,189,427,465],"DREAMM-7":[2,83,467],"(NCT04246047),":[3],"belantamab":[4],"mafodotin":[5],"(belamaf)":[6],"plus":[7],"bortezomib":[8],"and":[9,16,29,59,79,111,159,171,175,292,358,413,436,455,488,507],"dexamethasone":[10,30],"(BVd)":[11],"demonstrated":[12],"a":[13,55,143,220],"statistically":[14],"significant":[15],"clinically":[17],"meaningful":[18],"progression-free":[19],"survival":[20,61],"(PFS)":[21],"benefit":[22],"vs":[23,233,241,263,277,290,300,338],"the":[24,82,178,185,200,207,226,234,267,308,335,345,363,410,414,442,466,471,481,485,518,521],"standard-of-care":[25],"triplet":[26],"daratumumab,":[27],"bortezomib,":[28],"(DVd)":[31],"in":[32,63,77,81,139,199,225,279,316,334,344,470,484],"patients":[33,140,192,224,251,283,293,321,329,343,367,428,451,469,490],"with":[34,88,118,260,284,294,305,322,324,355,362,390,498,504,513,528],"relapsed":[35],"or":[36,99,148,168],"refractory":[37,286],"multiple":[38,64],"myeloma":[39],"who":[40,141,368,429],"had":[41,229,452,461],"received":[42],"\u22651":[43,89,295],"prior":[44,90],"line":[45,91],"of":[46,57,92,155,223,238,243,250,271,282,320,326,340,395,450,520],"treatment.":[47],"MRD":[48,72,134,254,273,332,373,500],"negativity":[49,73,255,274,333,501],"has":[50],"been":[51],"shown":[52],"to":[53,69,75,97,287,349],"be":[54],"predictor":[56],"PFS":[58,78,156,357,376,393,435,453,506],"overall":[60],"(OS)":[62],"myeloma.":[65],"Here,":[66],"we":[67],"aimed":[68],"understand":[70],"if":[71],"translated":[74],"improvements":[76],"OS":[80,110,160,359,405,416,437,462,508],"trial.":[84],"Methods:":[85],"DREAMM-7,patients":[87],"treatment":[93],"were":[94,161,182,197,438],"randomized":[95,198],"(1:1)":[96],"BVd":[98,227,261,276,336,472],"DVd.":[100],"The":[101],"primary":[102],"endpoint":[103],"was":[104,123,136,314,353,377,406,418,502],"independent":[105],"review":[106],"committee":[107],"(IRC)-assessed":[108],"PFS.":[109],"aMRD":[112],"negative":[113,173],"status":[114,174,232,352,476,494],"by":[115,266,441],"next-generation":[116],"sequencing":[117],"10-5":[119],"sensitivity;":[120],"follow-up":[121],"testing":[122],"performed":[124,138,162],"every":[125],"6":[126],"months":[127,258,379,497],"thereafter":[128],"until":[129],"progressive":[130],"disease.":[131],"An":[132],"exploratory":[133,318],"analysis":[135,210,319],"also":[137],"achieved":[142,252,430,474,491,527],"very":[144],"good":[145],"partial":[146],"response":[147,166,523],"better":[149],"(\u2265VGPR).":[150],"Post":[151],"hoc":[152],"subgroup":[153],"analyses":[154],"(IRC":[157],"assessed)":[158],"based":[163],"on":[164],"IRC-assessed":[165],"(\u2265CR":[167],"\u2265":[169],"VGPR)":[170],"MRD-":[172],"evaluated":[176],"using":[177,184,546],"Kaplan-Meier":[179],"method;":[180],"CIs":[181],"estimated":[183],"Brookmeyer-Crowley":[186],"method.":[187],"Results:":[188],"total,":[190],"494":[191],"(BVd,":[193,446,457],"n=243;":[194],"DVd,":[195,387,402,425,448,459],"n=251)":[196],"intention-to-treat":[201,309,364],"population.":[202,365],"As":[203],"previously":[204],"reported,":[205],"at":[206,409,477],"first":[208],"interim":[209],"(data":[211],"cutoff:":[212],"October":[213],"2,":[214],"2023;":[215],"median":[216,375,404,434],"follow-up,":[217],"28.2":[218],"months),":[219,389],"higher":[221,248],"proportion":[222,249],"arm":[228,236,337,473],"CR-based":[230,272,372,431],"MRD-negative":[231,351,432,475,493],"DVd":[235,264,278,346,486],"(60":[237],"243":[239,327],"[25%]":[240],"24":[242],"251":[244,341],"[10%]":[245],"patients).":[246],"A":[247,311],"sustained":[253,492],"for":[256,495],"\u226512":[257,496],"(\u2265CR)":[259],"(10%)":[262],"(2%)":[265],"data":[268,411,443],"cutoff.":[269],"Rates":[270],"favored":[275],"prespecified":[280],"subgroups":[281],"disease":[285],"lenalidomide":[288],"(25%":[289],"6%)":[291],"high-risk":[296],"cytogenetic":[297],"abnormality":[298],"(31%":[299],"7%);":[301],"this":[302,516],"is":[303,511,526],"consistent":[304,512],"findings":[306],"from":[307,540,550],"analysis.":[310],"similar":[312],"trend":[313],"observed":[315,483],"an":[317,391],"\u2265VGPR,":[323],"94":[325],"(39%)":[328],"achieving":[330],"VGPR-based":[331],"43":[339],"(17%)":[342],"arm.":[347],"Inability":[348],"achieve":[350,371],"associated":[354,503],"lower":[356],"outcomes":[360],"compared":[361],"Among":[366],"did":[369],"not":[370,407,439],"negativity,":[374],"15.3":[378],"(95%":[380,397,420],"CI,":[381,398,421],"12.7-18.0":[382],"months;":[383,386],"BVd,":[384,400,423],"25.0":[385],"11.8":[388],"18-month":[392,415],"rate":[394,417,482],"45%":[396],"40%-50%;":[399],"57%;":[401],"36%);":[403],"reached":[408],"cutoff,":[412,444],"74%":[419],"69%-78%;":[422],"79%;":[424],"70%).":[426],"status,":[433],"reached;":[440],"13%":[445],"10%;":[447],"21%)":[449],"events,":[454],"5%":[456],"5%;":[458],"4%)":[460],"events.":[463],"Conclusions:":[464],"trial,":[468],"more":[478,489],"than":[479],"double":[480],"arm,":[487],"BVd.":[499,529],"durable":[505],"benefits,":[509],"which":[510],"previous":[514],"reports;":[515],"highlights":[517],"importance":[519],"greater":[522],"depth":[524],"that":[525],"Funding":[530],"statement:":[531],"GSK":[532],"(Study":[533],"#":[534],"207503)":[535],"Drug":[536],"linker":[537],"technology":[538],"licensed":[539,549],"Seagen":[541],"Inc.;":[542],"monoclonal":[543],"antibody":[544],"produced":[545],"POTELLIGENT":[547],"Technology":[548],"BioWa.":[551]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-12-06T00:00:00"}